Last update Dec. 21, 2013


High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Anti-HIV drug. No experience in young infants.

Withdrawn from market.

Mothers should be aware of HIV transmission through breast milk has been reported.


  • Lamivudine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nevirapine (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Tenofovir Disoproxil Fumarate (TDF) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Zidovudine (ZDV) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Amprenavir belongs to this group or family:


Main tradenames from several countries containing Amprenavir in its composition:


Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 506 daltons
Protein Binding 90 %
VD 6 l/Kg
Tmax 1 - 2 hours
T1/2 7.1 - 10.6 hours


  1. EMEA Amprenavir Fiche técnica 2009 Full text (in our servers)
  2. EMEA Amprenavir Data Sheet 2009 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM